lp-a.org

Library 1702 studies · 120 landmark

The canon (discovery, genetics, the consensus documents, every trial of an Lp(a)-specific agent, the trial biobank analyses) and the newest publications, grouped by primary topic and ranked by significance. Archive by year · How items are chosen and scored.

RNA therapeuticsOral inhibitionApheresisPCSK9 inhibitionCETP inhibitionStatinsAortic stenosisGeneticsTestingGuidelinesInflammationMechanismsEpidemiologyTherapy

RNA therapeutics 198

Antisense and siRNA agents against LPA: phase 1 to 3.

186 more in RNA therapeutics

Oral inhibition 7

Muvalaplin, the small-molecule inhibitor of Lp(a) assembly.

Apheresis 34

Lipoprotein apheresis: the German cohorts and its replacement.

22 more in Apheresis

PCSK9 inhibition 85

What evolocumab, alirocumab and inclisiran do to Lp(a) and to risk.

73 more in PCSK9 inhibition

CETP inhibition 7

Obicetrapib and the class effect on Lp(a).

Statins 43

Statins raise Lp(a) modestly; risk on statins persists.

31 more in Statins

Aortic stenosis 95

Lp(a) as a cause of calcific aortic valve disease.

83 more in Aortic stenosis

Genetics 250

LPA, kringle IV repeats and the Mendelian randomisation evidence.

238 more in Genetics

Testing 263

Assays, units, thresholds and testing rates.

251 more in Testing

Guidelines 17

Consensus and guideline documents.

5 more in Guidelines

Inflammation 100

CRP, IL-6, oxidised phospholipids and Lp(a) risk.

88 more in Inflammation

Mechanisms 135

How the particle does its damage.

123 more in Mechanisms

Epidemiology 414

Cohorts, biobanks and registries.

402 more in Epidemiology

Therapy 54

What can be done today.

42 more in Therapy